Clinical trial
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
NCT04641247 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 16, 2021
- Completion date
- December 28, 2026
- Enrollment
- 37 (estimated)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.